<DOC>
	<DOCNO>NCT02533375</DOCNO>
	<brief_summary>The primary objective investigate efficacy , safety pharmacokinetics adalimumab Japanese subject generalize pustular psoriasis ( GPP ) .</brief_summary>
	<brief_title>Study Investigate Efficacy Safety Adalimumab Japanese Subjects With Generalized Pustular Psoriasis ( GPP )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis generalize pustular psoriasis Total skin score least 3 erythema pustule Baseline Japan Dermatology Association ( JDA ) severity index Generalized Pustular Psoriasis ( GPP ) GPP Medical Care Guideline 2014 Japan Inadequate response , intolerance , contraindication approve GPP treatment ( exclude infliximab ) Infliximab secondary failure , intolerant infliximab Erythrodermic psoriasis , guttate psoriasis subcorneal pustular dermatosis Druginduced GPP Can stop ongoing use prohibit GPP treatment Total JDA severity index GPP 14</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>